Isabella Ciccone, MPH

Paula Emanuela Voinescu, MD, PhD, director of the Women's Epilepsy Program at Brigham and Women's Hospital, talked about the influence of sex hormones on maternal outcomes in pregnant women with epilepsy treated with antiseizure medication.

Kate Labiner, MD, a pediatric epileptologist at Child Neurology Consultants of Austin, talked about the potential of cenobamate in pediatric patients with refractory focal epilepsy who have failed multiple medications.

An analysis of a phase 3 trial of low sodium oxybate in patients with idiopathic hypersomnia identified a minimal clinically important difference in the visual analog scale for sleep inertia.

A phase 3b study showed that switching from intravenous C5 inhibitors to subcutaneous zilucoplan in patients with myasthenia gravis was associated with symptom improvement at 12 weeks.

Even at the highest modal dose range, findings from the phase 3 RISE-PD trial showed that IPX203 did not increase safety risks for patients with Parkinson disease over time.

New findings from the phase 3 PROOF-HD trial showed that pridopidine outperformed placebo up to 78 weeks in patients with Huntington disease even after excluding those on neuroleptics and antichorea medications.

ALKS 2680, an investigational orexin 2 receptor agonist, showed promise for improving sleep latency in patients with narcolepsy type 2 and idiopathic hypersomnia in a phase 1b study.

The FDA has approved a label update on the administration options for SK Life Science’s cenobamate, a treatment approved for adults with partial-onset seizures.

The executive vice president and chief research officer of the Muscular Dystrophy Association shared her reaction to the recent FDA approval of givinostat for Duchenne muscular dystrophy.

The first patient enrolled into the phase 1/2a ArthemiR trial assessing ATX-01 myotonic dystrophy type 1 is expected in the second quarter of 2024.

The newly cleared i-STAT TBI test can be used to help assess patients up to 24 hours after injury at patient bedside, with lab-quality results produced in 15 minutes.

A recent study indicated that certain antiseizure medications used in pregnant women with epilepsy had a lower risk of major congenital malformations.

A recent published letter affirmed the safety of cenobamate, an FDA-approved antiseizure medication, in a large global patient population.

Findings from a recent study revealed the significant influence of lysosomal polygenic burden on cognitive decline in patients Parkinson disease who also have a low risk of Alzheimer disease.

Although results from the phase 2 LixiPark trial showed that lixisenatide may slow motor symptom progression in early Parkinson disease, reported gastrointestinal adverse effects raise some safety considerations.

Amylyx Pharmaceuticals’ AMX0035, despite its safety profile, did not show significant efficacy among patients with amyotrophic lateral sclerosis in the phase 3 PHOENIX trial.

Allison Verhaak, PhD, a clinical psychologist from Ayer Neuroscience Institute at Hartford Healthcare Headache Center, shared her insights on a recent study that explored cannabis use among patients with headache and migraine.

As part of our monthly clinician spotlight, NeurologyLive® highlighted multiple sclerosis expert Scott Newsome, DO, MSCS, FAAN, FANA, director of the Stiff Person Syndrome Center and professor of neurology at Johns Hopkins Medicine.

A recent study presented key predictors of survival in patients living with Friedreich ataxia, which led to the creation of a prognostic model for disease management.

Newly approved treatments in neuromyelitis optica spectrum disorder have shown efficacy in recent years, yet unaddressed concerns voiced by clinicians and patients living with the disease remain.

A recent study revealed that digital composite measures for bradykinesia outperformed traditional assessment methods for Parkinson disease over a 12-month period.

At AD/PD 2024, AC Immune SA presented an update on the company's phase 2 VacSYn trial assessing ACI-7104.056, an anti-α-synuclein active immunotherapy, for patients with Parkinson disease.

The director of the Adult Genetic Epilepsy Program at the University of Toronto talked about the significant challenges posed by transitioning patients with epilepsy from pediatric to adult care settings.

The approval is supported by phase 3 data which showed ravulizumab-cwvz met its primary end point of time to first on-trial relapse, with no relapses observed in 58 patients with NMOSD over a median treatment duration of 73 weeks.

Branded as Duvyzat, givinostat is the first nonsteroidal drug approved to treat patients with all genetic variants of DMD.

Recent data highlighted the benefit of Gain Therapeutics’ GT-02287 mechanism of action in alleviating endoplasmic reticulum stress and enhancing lysosomal enzyme activity.

A phase 2a trial demonstrated significant cognitive improvement in patients with mild cognitive impairment or mild dementia from Alzheimer or Parkinson disease through combination adrenergic activator therapy.

In collaboration with Robert A. Hauser, MD, MBA, the survey aims to understand the impact of tremors in patients with Parkinson disease.

Revance’s daxibotulinumtoxinA-Ianm (Daxxify) is the first and only approved peptide-formulated, long-lasting neuromodulator for patients with cervical dystonia.

New findings from a phase 1 trial presented at AD/PD 2024 showed that UB-312 antibodies decrease α-synuclein levels in the cerebrospinal fluid of patients with Parkinson disease.